years and older (50 micrograms at least 4 months after their previous dose) Moderna Spikevax ®COVID-19 vaccine, Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1), Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5)

thanks for the tremendous contribution slewman. out of interest where did you get all the colours from? The Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA.1) is approved as a booster for people who are 6 years of age and older. Its safety and effectiveness in younger people has not yet been established. Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) Moderna Spikevax ® Monovalent Omicron COVID-19 vaccine (Omicron XBB.1.5 subvariant) regulatory information The Moderna Spikevax ® COVID-19 vaccine is approved for primary vaccination in people who are 6 months of age and older. Its safety and effectiveness in people younger than 6 months have not yet been established. This vaccine is also approved as a booster for people 12 years of age and older. Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.1)Reported allergic reactions and side effects to COVID-19 vaccines are published weekly in our Reported side effects following COVID-19 vaccination report. Vaccine review, approval and monitoring Primary series in individuals age 6 months and older, or as a booster dose in individuals age 12 years and older: Find detailed technical information such as the product monograph and the regulatory decision summary: A different vaccine may be offered for your second dose. For example, you may have received Pfizer-BioNTech Comirnaty ® as your first dose and be offered Moderna Spikevax ® as your second. This is known as a mixed vaccine series. Clinical trials showed that beginning 2 weeks after the second dose, the Moderna Spikevax ® COVID vaccine was:

The monovalent Omicron XBB 1.5 subvariant multi-dose vial has a royal blue plastic cap and coral blue label. After getting vaccinated, it's common to have temporary side effects. These can last a few hours to a few days after vaccination. The bivalent Original/Omicron BA.4/5 0.1 mg/mL multi-dose vial has a royal blue plastic cap and grey label. Your province or territory decides when people receive their doses of the vaccine. These decisions are based on public health recommendations and the latest evidence.Call emergency services if you develop or witness any serious symptoms that could be anallergic reactionafter vaccination. Reporting a possible serious reaction The Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) is approved as a booster for people who are 6 years of age and older. Its safety and effectiveness in younger people has not yet been established. Moderna Spikevax ®Monovalent COVID-19 vaccine (Omicron XBB.1.5 subvariant)

Its safety and effectiveness in people younger than 6 months has not yet been established. Effectiveness The Moderna Spikevax®Monovalent COVID-19 vaccine(Omicron XBB.1.5 subvariant) is approved for people who are 6 months of age and older. It may be given to people who have been previously vaccinated or who have not been previously vaccinated. The bivalent Original/Omicron BA.1 0.1 mg/mL multi-dose vial has a royal blue plastic cap and green label. The mRNA sequence from Moderna Spikevax ®COVID-19 vaccine is also included in the Moderna Spikevax ®Bivalent COVID-19 vaccine (Original/Omicron BA.4/5). The bivalent booster also has an additional mRNA sequence that targets the Omicron BA.4/5 variants. Other ingredients months to 4 years (25 micrograms at least 6 months after their previous dose). If the child has not been previously vaccinated, Spikevax XBB.1.5 should be administered a 2-dose regimen.Health care providers must report possible reactions following vaccination to their local public health authority. The public health authority then reports them to the Public Health Agency of Canada.